Kerala’s UDF government has constituted a medical board to determine whether expired doses of the antiviral drug Remdesivir contributed to six Nipah virus deaths between 2023 and 2025, after data showed the state used vials past their May 30, 2023 expiry date, The New Indian Express reported.
The probe lands at a sensitive moment for a state whose handling of the 2018 Nipah outbreak and subsequent occurrences earned global recognition for its public healthcare system. That reputation is now under challenge over inventory management, treatment protocols, and administrative accountability — questions the state’s own health minister has publicly raised.
Why the expired Remdesivir stock matters now
The controversy centers on 3,000 vials of Remdesivir procured by the state government in June 2021, all carrying an expiry date of May 30, 2023. Data from Kozhikode Medical College show that 102 of these vials were used in 2023-24, 34 in 2024-25, and 10 in 2025-26 — meaning 146 doses were administered after the labeled expiry date. Health Minister K Muraleedharan flagged the lapse, noting that the packages carried an expiry date but no manufacturing date, and that some stock was labeled “For clinical trial use.”
The minister’s disclosure triggered a sharp political backlash from the previous LDF regime, while critical care specialist Dr A S Anoop Kumar rebutted the suspicion, stating that none of the six Nipah fatalities between 2023 and 2025 had received Remdesivir from the medical college, as all six were diagnosed only after death.
Kerala is investigating whether expired Remdesivir was administered to Nipah patients at Kozhikode Government Medical College Hospital. The State Medical Services Corporation (KMSCL) last purchased 3,000 vials in June 2021. The stock expired on 30 May 2023. Hospital records… pic.twitter.com/nS59cV6N31
Explains drug’s unproven Nipah virus claims
- Remdesivir is an antiviral drug whose effectiveness against Nipah virus remains unproven — no treatment has conclusive evidence of working against this infection.
- Using medication past its labeled expiry date is a serious inventory failure, but it does not by itself prove the drug caused any death.
- Nipah virus is exceptionally lethal, with a high fatality rate, so deaths during an outbreak cannot automatically be blamed on any single medicine.
What the timeline shows, from 2018 to this week
Kerala’s handling of the first Nipah outbreak in 2018 became a defining chapter in the state’s healthcare journey, and its efforts drew international praise. The state procured the Remdesivir stock in June 2021, during the COVID-19 pandemic, when the drug was widely deployed against SARS-CoV-2. By May 30, 2023, the vials had expired — yet records from Kozhikode Medical College indicate continued use across three subsequent fiscal years.
Six Nipah deaths occurred between 2023 and 2025. The newly constituted medical board must now ascertain whether any of those patients received the expired Remdesivir and whether that played any role in their outcomes. Attributing deaths to expired medication without indisputable evidence would be irresponsible, as Nipah is an exceptionally dangerous infection and drug effectiveness against it remains far from conclusive. But that does not make the inventory questions any less serious: why was out-of-date medication retained, and was any of it administered to patients?
Comparing the claims: what is confirmed versus disputed
| Claim | Status | Source of record |
|---|---|---|
| 3,000 Remdesivir vials procured June 2021, expiring May 30, 2023 | Confirmed by state procurement records | Kozhikode Medical College data, reported by The New Indian Express |
| 102 vials used in 2023-24, 34 in 2024-25, 10 in 2025-26 | Confirmed by medical college usage data | Kozhikode Medical College data, reported by The New Indian Express |
| Expired Remdesivir contributed to the six Nipah deaths | Disputed — under investigation by the medical board | Allegation raised by Health Minister K Muraleedharan; rebutted by Dr A S Anoop Kumar |
The dispute is sharp. If that holds, the expired stock may never have touched a Nipah patient — which would shift the issue from a treatment failure to a pure governance failure in procurement, storage, and inventory management.
Why accountability must not become a political slugfest
Any lapse in procurement, storage, or inventory management must be identified and responsibility fixed. If the probe leads to a better treatment protocol, that would be a bonus for a state battling recurring Nipah outbreaks. However, accountability must not become a pretext for discrediting a healthcare system built over decades. Kerala’s system must remain open to scrutiny precisely because its achievements are worth protecting. The priority is to establish facts, address systemic deficiencies, and strengthen public confidence — not to score political points.
Kerala has ordered a medical board probe into whether expired Remdesivir vials administered to Nipah patients between 2023 and 2025 contributed to six deaths. #Kerala #NipahVirus #Remdesivir #HealthProbe #HealthcareSafety 🔗https://t.co/eLUf4LD4M1 pic.twitter.com/uUZWqukMaO
Identifies symptoms and warns against self-use
Nipah virus infection has no approved specific antiviral treatment; care is supportive, focusing on hydration, fever management, and intensive monitoring for respiratory and neurological complications. Anyone in an affected region who develops sudden fever, headache, vomiting, or drowsiness should seek emergency medical evaluation immediately, and suspected cases require strict isolation to prevent person-to-person transmission. Remdesivir should never be self-administered or obtained outside regulated clinical settings, and any medication past its labeled expiry date should not be used.
The medical board’s findings in the coming weeks will determine whether this episode becomes a case study in systemic failure — or a demonstration that Kerala’s celebrated healthcare machinery can police itself.
References
- The New Indian Express — reporting on the Kerala Nipah probe, Remdesivir procurement and usage data from Kozhikode Medical College, and statements by Health Minister K Muraleedharan and Dr A S Anoop Kumar
More on Kerala Nipah
Expired Remdesivir Given to Nipah Patients in Kerala, Probe Orderedhttps://t.co/HgidnmdPYs
Expired Remdesivir Given to Nipah Patients in Kerala, Govt Orders Probehttps://t.co/zDcJkvSYt3#Kerala #Remdesivir #NipahVirus #DrugSafety #KMuraleedharan #Kozhikode #HealthNews #MedicalInvestigation
